IL292970A - Treatment and prevention of dengue disease - Google Patents
Treatment and prevention of dengue diseaseInfo
- Publication number
- IL292970A IL292970A IL292970A IL29297022A IL292970A IL 292970 A IL292970 A IL 292970A IL 292970 A IL292970 A IL 292970A IL 29297022 A IL29297022 A IL 29297022A IL 292970 A IL292970 A IL 292970A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- copies
- dengue
- medicament
- hours
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19209593 | 2019-11-15 | ||
| EP19213851 | 2019-12-05 | ||
| EP20171172 | 2020-04-23 | ||
| PCT/EP2020/082102 WO2021094563A1 (en) | 2019-11-15 | 2020-11-13 | Treatment and prevention of dengue disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292970A true IL292970A (en) | 2022-07-01 |
Family
ID=73288639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292970A IL292970A (en) | 2019-11-15 | 2020-11-13 | Treatment and prevention of dengue disease |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220409583A1 (https=) |
| EP (1) | EP4058019A1 (https=) |
| JP (1) | JP2023502053A (https=) |
| KR (1) | KR20220101679A (https=) |
| CN (1) | CN114980884A (https=) |
| AU (1) | AU2020382911A1 (https=) |
| BR (1) | BR112022009199A2 (https=) |
| CA (1) | CA3161338A1 (https=) |
| IL (1) | IL292970A (https=) |
| MX (1) | MX2022005879A (https=) |
| PH (1) | PH12022551160A1 (https=) |
| TW (1) | TW202132269A (https=) |
| UA (1) | UA129409C2 (https=) |
| WO (1) | WO2021094563A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023218285A1 (en) * | 2022-05-12 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Treatment or prevention of dengue viral infection |
| WO2025248536A1 (en) * | 2024-05-29 | 2025-12-04 | Zydus Lifesciences Limited | Novel oxime derivatives to treat viral infections |
| WO2025253267A1 (en) | 2024-06-06 | 2025-12-11 | Janssen Pharmaceuticals, Inc. | Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
-
2020
- 2020-11-13 CA CA3161338A patent/CA3161338A1/en active Pending
- 2020-11-13 WO PCT/EP2020/082102 patent/WO2021094563A1/en not_active Ceased
- 2020-11-13 AU AU2020382911A patent/AU2020382911A1/en active Pending
- 2020-11-13 MX MX2022005879A patent/MX2022005879A/es unknown
- 2020-11-13 EP EP20803432.2A patent/EP4058019A1/en active Pending
- 2020-11-13 UA UAA202202003A patent/UA129409C2/uk unknown
- 2020-11-13 PH PH1/2022/551160A patent/PH12022551160A1/en unknown
- 2020-11-13 JP JP2022528008A patent/JP2023502053A/ja active Pending
- 2020-11-13 US US17/777,019 patent/US20220409583A1/en active Pending
- 2020-11-13 IL IL292970A patent/IL292970A/en unknown
- 2020-11-13 TW TW109139793A patent/TW202132269A/zh unknown
- 2020-11-13 BR BR112022009199A patent/BR112022009199A2/pt unknown
- 2020-11-13 CN CN202080093897.0A patent/CN114980884A/zh active Pending
- 2020-11-13 KR KR1020227020173A patent/KR20220101679A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220101679A (ko) | 2022-07-19 |
| UA129409C2 (uk) | 2025-04-16 |
| CA3161338A1 (en) | 2021-05-20 |
| EP4058019A1 (en) | 2022-09-21 |
| JP2023502053A (ja) | 2023-01-20 |
| TW202132269A (zh) | 2021-09-01 |
| US20220409583A1 (en) | 2022-12-29 |
| CN114980884A (zh) | 2022-08-30 |
| PH12022551160A1 (en) | 2023-09-25 |
| WO2021094563A1 (en) | 2021-05-20 |
| MX2022005879A (es) | 2022-06-14 |
| AU2020382911A1 (en) | 2022-06-30 |
| BR112022009199A2 (pt) | 2022-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292970A (en) | Treatment and prevention of dengue disease | |
| WO2022035911A2 (en) | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent | |
| AU2014318488B2 (en) | Deoxynojirimycin derivatives and methods of their using | |
| CN109789147B (zh) | 用于治疗非酒精性脂肪性肝病的药物组合物及方法 | |
| AU2019213440B2 (en) | Method of viral inhibition | |
| AU2014228035B2 (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
| WO2017223178A1 (en) | Treating viral infections with impdh inhibitors | |
| Snell | Examining unmet needs in infectious disease | |
| Yeh et al. | mk-8742, a Hcv Ns5a Inhibitor with a Broad Spectrum of Hcv Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotype-1 and-3 Hcv-infected Patients: 479 | |
| EA049504B1 (ru) | Лечение и профилактика лихорадки денге | |
| CN102335171B (zh) | 一类n-(2-噻唑)苯甲酰胺衍生物的应用 | |
| US11975003B2 (en) | Methods and compositions for treatment of Zika virus infection | |
| HK40074715A (en) | Treatment and prevention of dengue disease | |
| CN113440527B (zh) | 萘酚喹或含萘酚喹的组合制剂在抗冠状病毒中的应用 | |
| US11000516B2 (en) | Dosing regimens of celgosivir for the prevention of dengue | |
| Pashaei | Fluoxetine and molnupiravir: a synergistic combination for COVID-19 treatment? | |
| JP2023543969A (ja) | ウイルス感染の治療及び／又は予防 | |
| US20170348330A1 (en) | Antiviral compound and analogues thereof for treatment or prevention of flavivirus dengue/zika infections | |
| CN106727574A (zh) | 马尼地平在制备治疗黄病毒科病毒感染药物中的应用 | |
| KR20120071376A (ko) | 설폰아미드계 화합물을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물 | |
| Zhao et al. | IN VITRO COMBINATION STUDIES OF ACH-1625 (HCV NS3 PROTEASE INHIBITOR) AND ACH-2928 (HCV NS5A INHIBITOR) IN PRESENCE AND ABSENCE OF RIBAVIRIN: 1880 | |
| Dodd et al. | Duloxetine for major depression |